BDBM802075 (2S,4R)-4-hydroxy-N-((S)-1- (4-(4-methylthiazol-5-yl)phen- yl)ethyl)-1-((R)-3,7,7-trimeth- yl-5,6,7,8-tetrahydro-4H- cyclohepta[d]isoxazole-8- carbonyl)pyrrolidine-2- carboxamide::US20260108613, Compound A22

SMILES Cc1ncsc1-c1ccc([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]2c3onc(C)c3CCCC2(C)C)cc1

InChI Key

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 802075   

Targetvon Hippel-Lindau disease tumor suppressor(Human)
University of Michigan

US Patent
LigandChemical structure of BindingDB Monomer ID 802075BDBM802075((2S,4R)-4-hydroxy-N-((S)-1- (4-(4-methylthiazol-5-...)
Affinity DataIC50: 35nMAssay Description:JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
9/2/2026
Entry Details
US Patent